Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 4, 2008, Pages 384-389

  Balassoulis, George ^a   Sichletidis, Lazaros ^a,b   Spyratos, Dionisios ^a   Chloros, Diamantis ^a   Zarogoulidis, Kostas ^a   Kontakiotis, Theodoros ^a   Bagalas, Vassilios ^a   Porpodis, Kostas ^a   Manika, Katerina ^a   Patakas, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

Erythromycin; Malignant pleural effusion; Pleurodesis; Sclerosing agent

Indexed keywords

DEXTROPROPOXYPHENE; ERYTHROMYCIN; PARACETAMOL; ANTIINFECTIVE AGENT; SCLEROSING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; DRAIN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; HYPERTENSION; MALE; OUTCOME ASSESSMENT; PLEURA EFFUSION; PLEURA FLUID; PLEURAL PAIN; PLEURODESIS; REPEATED DRUG DOSE; SINUS TACHYCARDIA; SURVIVAL TIME; TREATMENT RESPONSE; TUBE; ADENOCARCINOMA; BREAST TUMOR; KIDNEY TUMOR; PATHOLOGY; RECURRENT DISEASE; SAFETY; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; WOUND DRAINAGE;

ADENOCARCINOMA; AGED; ANTI-BACTERIAL AGENTS; BREAST NEOPLASMS; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; DRAINAGE; ERYTHROMYCIN; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; RECURRENCE; SAFETY; SCLEROSING SOLUTIONS; TREATMENT OUTCOME;

EID: 55449095868     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318165c061     Document Type: Article

References (41)

1. Chernow B, Sahn SA. Carcinomatous involvement of the pleura. Am J Med. 1977;63:695-702.
2. Molengraft van de FJJM, Vooijs GP. Survival of patients with malignancy-associated effusions. Acta Cytol. 1989;33:911-916.
3. DiBonito L, Falconieri G, Colautti I, et al. The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol. 1992;36:329-332.
4. Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58(Suppl II):S29-S38.
5. Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer. 1985; 56:905-909.
6. Hsu C. Cytologic detection of malignancy in pleural effusion: a review of 5255 samples from 3811 patients. Diagn Cytopathol. 1987;3:8-12.
7. Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272.
8. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev. 2004;(1):CD002916.
9. Rinaldo JE, Owens GR, Rogers RM. Adult respiratory distress syndrome following intrapleural installation of talc. J Thorac Cardiovasc Surg. 1983;85:523-526.
10. Campos JR, Werede EC, Vargas FS, et al. Respiratory failure due to insufflated talk. Lancet. 1997;349:251-252.
11. Light RW. Talc should not be used for pleurodesis. Am J Respir Crit Care Med. 2000;162:2024-2026.
12. Lee YCG, Light RW. Management of malignant pleural effusions. Respirology. 2004;9:148-156.
13. Lee YCG, Baumann MH, Maskell NA, et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey among pulmonologists. Chest. 2003;124:2229-2238.
14. Carvahlo P, Knight LL, Olson RD, et al. Effects of erythromycin on the rabbit pleura: its potential role as a pleural sclerosant. Am J Respir Crit Care Med. 1995;151:1228-1232.
15. Ruckdeschel JC, Moores D, Lee JY, et al. Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. Chest. 1991;100:1528-1535.
16. Barbetakis N, Antoniadis T, Tsilikas C. Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer. World J Surg Oncol. 2004;2:16.
17. Bonnefoi H, Smith IE. How should cancer presenting as a malignant effusion be managed? Br J Cancer. 1996;74:832-835.
18. Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J. 1997;10:1907-1913.
19. Hartman DL, Gaither JM, Kesler KA, et al. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg. 1993;105:743-748.
20. Patz EF, McAdams HP, Erasmus JJ, et al. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest. 1998;113: 1305-1311.
21. Martinez-Moragon E, Aparicio J, Rogado MC, et al. Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J. 1997;10:2380-2383.
22. Lynch TJ, Kalish L, Mentzer SJ, et al. Optimal therapy of malignant pleural effusions: report of a randomized trial of bleomycin, tetracycline and talc and a meta-analysis. Int J Oncol. 1996;8:183-190.
23. Zimmer PW, Hill M, Casey K, et al. Prospective randomized trial of talc slurry vs bleomycin in pleurodesis for symptomatic malignant pleural effusions. Chest. 1997;112:430-434.
24. Heffner EJ, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure. Chest. 2000;117:87-95.
25. Diacon AH, Wyser C, Bolliger CT, et al. Prospective randomized comparison of thoracoscopic talc poudrage under local anaesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med. 2000;162:1445-1449.
26. Ong KC, Indumathi V, Raghuram J, et al. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant effusions. Respirology. 2004;5:99-103.
27. West SD, Davies RJO, Lee YCG. Pleurodesis for malignant pleural effusions: current controversies and variations in practices. Curr Opin Pulm Med. 2004;10:305-310.
28. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med. 1994;120:56-64.
29. Kennedy L, Sahn SA. Talc pleurodesis for the treatment of pneumothorax and pleural effusion. Chest. 1994;106:1215-1222.
30. Sahn SA. Malignant pleural effusions. In: Bouros D, ed. Pleural Disease. New York, NY: Marcel Dekker; 2004:411-438.
31. Maskell NA, Lee YCG, Gleeson FV, et al. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med. 2004;170:377-382.
32. Yim AP, Chan AT, Lee TW, et al. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusions. Ann Thorac Surg. 1996;62:1655-1658.
33. Evans TR, Stein RC, Pepper JR, et al. A randomized prospective trial of surgical against medical tetracycline pleurodesis in the management of malignant pleural effusions secondary to breast cancer. Eur J Cancer. 1993;29:316-319.
34. Dresler CM, Olak J, Herndon JE, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127:909-915.
35. Xie C, Huang JQ, Light RW. The effects of erythromycin on the viability and the secretion of TNF-α and TGF-β1 and expression of connexion 43 by human pleural mesothelial cells. Respirology. 2005; 10:567-571.
36. Tang X, Cheng D. The value of erythromycin pleurodesis in the treatment of malignant pleural effusions. Hua Xi Yi Ke Da Xue Xue Bao. 1997;28:437-439.
37. Zeng M, Xie CM, Wu JF, et al. The value of erythromycin pleurodesis in the treatment of pneumothorax. Chin J Respir Crit Care Med. 2004;3:110-112.
38. Gilter B, Berger LS, Buffa SD. Torsades de pointes induced by erythromycin. Chest. 1994;105:368-372.
39. Saffran L, Ost DE, Fein AM, Schiff MJ. Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter. Chest. 2000;118:417-421.
40. Parulekar W, Di Primio G, Matzinger F, et al. Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions. Chest. 2001;120:19-25.
41. Sahin Ü , Ü nlü M, Akkaya A, et al. The value of small-bore catheter thoracostomy in the treatment of malignant pleural effusions. Respiration.2001;68:501-505.